Skip to content
OpenCapital
Get started

Viridian Therapeutics, Inc. VRDN Q1 2026 earnings

Reported May 5, 2026 · Before market open

Revenue$141.0KBeat by $104.9K
EPS-$0.90Beat by $0.16
Revenue estimate$36.1K
EPS estimate-$1.06

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$30.5K
EPS estimate-$1.02

Financials

Q1 2026

Income statement

See full
Revenue$141.0K+95.8%
Operating income-$116.2M-23.8%
Net income-$104.9M-20.7%

Balance sheet

See full
Cash & equivalents$176.3M+51.7%
Total debt$36.8M+59.4%
Total equity$636.0M+5.2%
Total assets$789.0M+19.4%

Cash flow

See full
Operating cash flow-$119.7M-29.1%
CapEx$23.0K-73.3%
Free cash flow-$119.7M-29.0%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$2.18B+54.5%
Enterprise value$2.04B+54.9%
P/S30.7×-4,587×

Profitability

See full
Operating margin-543.9%-271pp
Net margin-508.5%-254pp
FCF margin-428.4%-214pp

Returns & leverage

See full
Return on equity-58.1%+7.9pp
Debt / equity0.1×0.0×
Current ratio15.1×-4.3×

Segments

By product

See full
Collaboration$135.0K—
License$6.0K—

Versus estimates

Revenue

Q1 2026$141.0KBeat by $104.9K
Q4 2025$132.0KMiss by $18.2MQ3 2025$70.6MBeat by $54.8MQ2 2025$75.0KQ1 2025$72.0KBeat by $27.9KQ4 2024$72.0KBeat by $22.0K

Diluted EPS

Q1 2026-$0.90Beat by $0.16
Q4 2025-$1.08Miss by $0.18Q3 2025-$0.34Beat by $0.48Q2 2025-$1.00In lineQ1 2025-$0.87Beat by $0.08Q4 2024-$0.81Beat by $0.24

Ask the moment Viridian Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Viridian Therapeutics, Inc. report Q1 2026 earnings?
Viridian Therapeutics, Inc. (VRDN) reported Q1 2026 earnings on May 5, 2026 before market open.
What were Viridian Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Viridian Therapeutics, Inc. reported revenue of $141.0K and eps of $-0.90 for Q1 2026.
Did Viridian Therapeutics, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $36.1K by $104.9K. EPS beat the consensus estimate of $-1.06 by $0.16.
How did Viridian Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 95.8% from $72.0K a year earlier and eps declined 3.4% from $-0.87.
Where can I find Viridian Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-205010) and the 10-Q periodic report (0001590750-26-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.